Oral Wegovy Arrives in Israel, Offering Potent Weight Loss Alternative
Translated & summarized from Panet by baba
The oral version of the weight-loss drug Wegovy, demonstrating efficacy similar to its injectable form, is expected to be available in Israel by late October. Clinical trials show an average 16.6% body weight reduction, with over a third losing 20% or more. The drug, containing semaglutide, is approved by the FDA and EMA and will be offered in four dosages, with private market costs ranging from 640 to 1,260 shekels.
The story in 6 lines · by baba
- Oral Wegovy, a new weight-loss tablet, is expected to be available in Israel by the end of October.
- Clinical trials show the oral drug achieved an average 16.6% body weight reduction.
- Over a third of patients taking oral Wegovy lost 20% or more of their body weight.
- The drug contains semaglutide and mimics the appetite-regulating GLP-1 hormone.
- Patients switching from injectable weight-loss drugs to oral Wegovy experienced further weight loss.
- Oral Wegovy is approved by the FDA and EMA and will be available in four dosages.
A new oral tablet form of the weight-loss drug Wegovy, demonstrating efficacy comparable to its injectable counterpart, is set to become available in Israel by the end of October. The drug, which contains semaglutide, mimics the GLP-1 hormone to regulate appetite and promote satiety, leading to reduced food intake and weight loss. Clinical trials published in the New England Journal of Medicine showed an average body weight reduction of 16.6% over 64 weeks in patients taking the 25mg oral dose, compared to 2.7% in a placebo group. Notably, over a third of participants (34.4%) achieved a weight loss of 20% or more, significantly outperforming the placebo group's 2.9%.
The oral formulation is intended for individuals who prefer tablets over injections or wish to transition from injections to maintain or continue weight loss. An additional study presented at the European Society for Study of Diabetes conference indicated that patients switching from injectable weight-loss treatments to the oral Wegovy experienced a further average weight loss of approximately 4 kilograms (4.1% of body weight) within three months, with about 41% achieving at least a 5% additional reduction.
Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the oral Wegovy. The drug is currently undergoing registration in Israel and will be offered in four dosages: 1.5mg, 4mg, 9mg, and 25mg. The cost in the private market is expected to range between 640 and 1,260 Israeli shekels. The drug is produced by Novo Nordisk and is reported to be about 35% more effective in weight reduction than oral medications from the company Eli Lilly.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 1Arab 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
